No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 36 of the 40 quarters in the window, leaving 4 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 2905.6x · 10Y median 905.5x · 71st percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T20:08:11.892Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Pulse Biosciences, Inc. (PLSE) stock was $49.75 as of Oct 6, 2026, 4:00 PM EDT, down 1.49% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +160.6% · 3-year avg +129.8%/yr · 5-year avg +19.8%/yr
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine.
Medical - Instruments & Supplies · Miami, FL
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2022-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2022-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
-0.35
Revenue Est.
$604167.00
Last Quarter Results
EPS
$-0.28
vs Estimate
$-0.28
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PLSE | $3.44B | $49.75 | -1.49% | +160.60% | +19.76% | +23.22% | N/A |
| 2CELC | $3.47B | $71.25 | -3.22% | +45.49% | +34.40% | N/A | vs PLSE |
| 3IDYA | $3.48B | $36.63 | -3.76% | +37.49% | +7.32% | N/A | vs PLSE |
| 4ACAD | $3.38B | $19.74 | -1.84% | -7.72% | +3.52% | -3.53% | vs PLSE |
| 5PBLS | $3.36B | $28.86 | -2.27% | N/A | N/A | N/A | vs PLSE |
| 6IRTC | $3.52B | $107.20 | -1.73% | -37.74% | +12.95% | N/A | vs PLSE |
forward FY estimate
N/A
$434000.00
vs Estimate
$500000.00
Consensus Rating
Based on 6 analysts
Average Price Target
$54.00
+8.5% upside
Low
$35.00
Current
$49.75
High
$73.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.33 | $-0.31 | $-0.26 | 2 |
| Quarter ending Dec 2026 | $-0.34 | $-0.32 | $-0.26 | 2 |
| Quarter ending Mar 2027 | $-0.35 | $-0.33 | $-0.27 | 1 |
| Quarter ending Jun 2027 | $-0.36 | $-0.33 | $-0.27 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.36 | $-1.18 | $-0.24 | 3 |
| FY 2027 | $-2.51 | $-1.25 | $-0.26 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $525603.00 | $604167.00 | $641789.00 | 3 |
| Quarter ending Dec 2026 | $713369.00 | $820000.00 | $871062.00 | 3 |
| Quarter ending Mar 2027 | $951522.00 | $1.09M | $1.16M | 1 |
| Quarter ending Jun 2027 | $1.29M | $1.48M | $1.57M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.71M | $2.30M | $2.89M | 4 |
| FY 2027 | $5.17M | $6.72M | $8.27M | 4 |
